These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 11475274)

  • 1. Obesity medications and the treatment of type 2 diabetes.
    Greenway F
    Diabetes Technol Ther; 1999; 1(3):277-87. PubMed ID: 11475274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
    Gokcel A; Gumurdulu Y; Karakose H; Melek Ertorer E; Tanaci N; BascilTutuncu N; Guvener N
    Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
    Scheen AJ; Ernest P
    Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new role of pharmacotherapy for weight reduction in obesity.
    Fernstrom MH; Fernstrom JD
    Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.
    Miles JM; Leiter L; Hollander P; Wadden T; Anderson JW; Doyle M; Foreyt J; Aronne L; Klein S
    Diabetes Care; 2002 Jul; 25(7):1123-8. PubMed ID: 12087008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of diabetes in patients with severe obesity.
    Scheen AJ
    Biomed Pharmacother; 2000 Mar; 54(2):74-9. PubMed ID: 10759290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing type 2 diabetes mellitus in patients with obesity.
    Hauner H
    Treat Endocrinol; 2004; 3(4):223-32. PubMed ID: 16026105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining behavioral and pharmacological treatments for obesity.
    Phelan S; Wadden TA
    Obes Res; 2002 Jun; 10(6):560-74. PubMed ID: 12055334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term pharmacotherapy for obesity.
    Klein S
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity and type 2 diabetes: a conflict of interests?
    Williams G
    Int J Obes Relat Metab Disord; 1999 Jun; 23 Suppl 7():S2-4. PubMed ID: 10455464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
    Chou KM; Huang BY; Fanchiang JK; Chen CH
    Chang Gung Med J; 2007; 30(6):538-46. PubMed ID: 18350737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes.
    Kaukua JK; Pekkarinen TA; Rissanen AM
    Int J Obes Relat Metab Disord; 2004 Apr; 28(4):600-5. PubMed ID: 14770192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of antiobesity medications in patients with type 2 diabetes mellitus.
    Choussein S; Makri AA; Frangos CC; Petridou ET; Daskalopoulou SS
    Diabetes Obes Metab; 2009 Jul; 11(7):641-64. PubMed ID: 19236442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic options for modifying cardiometabolic risk factors.
    Aronne LJ
    Am J Med; 2007 Mar; 120(3 Suppl 1):S26-34. PubMed ID: 17320519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orlistat and sibutramine beyond weight loss.
    Mannucci E; Dicembrini I; Rotella F; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
    Elfhag K; Finer N; Rössner S
    Diabetes Obes Metab; 2008 Jun; 10(6):498-505. PubMed ID: 17593239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
    Wadden TA; Berkowitz RI; Womble LG; Sarwer DB; Arnold ME; Steinberg CM
    Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic agents for the treatment of obesity.
    Mathys M
    Clin Geriatr Med; 2005 Nov; 21(4):735-46, vii. PubMed ID: 16182086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Is type-2 diabetes mellitus preventable?].
    Jermendy G
    Orv Hetil; 2003 Sep; 144(39):1909-17. PubMed ID: 14598569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.